Since the discovery of amphotericin B and its subsequent introduction to the pharmaceutical market in the 1950s, treatment with this agent has been the standard to which all therapy for systemic fungal infection has been compared [I] . The subsequent introduction of clotrimazole, miconazole, and ketoconazole demonstrated the potential of the azole agents to supplant amphotericin B in at least a few of the diseases in which its use is indicated [2] . The potential importance of flucytosine was diminished by the relatively rapid development of resistance to· the agent and by its toxicities. Fluconazole has been the only serious competitor to amphotericin B; because of its oral absorption, availability as a parenteral agent, CNS penetration, and relative lack of toxicity, it is being seriously considered as a potential agent of choice for selected cases of cryptococcal meningitis, disseminated candidiasis, and certain forms of coccidioidomycosis [2] . The subsequent introduction of itraconazole has provided an agent with excellent potential in the treatment of several of the endemic mycoses [3] .
The availability of these products with their newly approved clinical indications has led many physicians to ask where amphotericin B now stands as the gold standard antifungal agent. This paper will examine the current state of the art in antifungal therapy and give recommendations with regard to the conduct of future clinical trials using this group of agents; it specifically addresses the role of amphotericin B as a comparative agent in these trials.
Current Status of Amphotericin B
The most recent edition of a standard textbook on infectious diseases summarizes expert opinion on the current status of antifungal therapy. For candidiasis, "Amphotericin B remains the cornerstone of therapy for disseminated and deep organ Candida infection, until more comparative data of the efficacy of amphotericin B vs. azoles are obtained" [4] . This statement must be modified by the findings in a trial of fluconazole versus amphotericin B in treatment of candidemia [5] . For aspergillosis, "Intravenous amphotericin B remains the drug of choice ... but response is poor in markedly immunosuppressed patients" [6] . Similarly, "The standard therapy for invasive mucormycosis is treatment with amphotericin B" [7] .
For the endemic mycoses, such as histoplasmosis, "Amphotericin B continues to be the drug of choice for life-threatening disease and for infections either unresponsive to azole therapy or relapsing after adequate azole treatment" [8] . For blastomycosis, "Amphotericin B was previously considered the treatment of choice for all clinical forms of blastomycosis. However, recent studies indicate that either ketoconazole or itraconazole is an effective alternative in immunocompetent patients with mild to moderate disease" [9] . Hence the milder forms of histoplasmosis and blastomycosis may readily be controlled or cured with azole therapy.
The author's suggested current recommendations for the treatment of systemic mycoses manifested as mild, moderate, and severe disease are presented in table 1. Definitions of mild, moderate, and severe are as follows: mild, "patient ambulatory and/or tolerates oral therapy"; moderate, "significant but not immediately life-threatening disease, patient could tolerate oral therapy"; and severe, "worst case scenario of host and site of infection. " Thus, amphotericin B is still considered to be the drug of first choice in the treatment of life-threatening disease. To some extent, this is due to the unpredictable absorption of ketoconazole and itraconazole in the presence of severe illness and antacid therapy [5, 10, 11] .
Situations in Which Amphotericin B Therapy Should Be Used First, Followed by an Oral Agent of Choice
While there has not been a significant number of clinical trials in which different drugs were used to treat different phases of illness, it makes sense that once an individual with serious illness has shown a significant clinical response to treatment with a parenteral or first-choice agent, therapy could be completed with an agent that has been shown to be effective in mild to moderate disease; for example, amphotericin B therapy that controls significant pulmonary or disseminated histoplasmosis could be followed by itraconazole therapy for an appropriate length of time. These suggestions are summarized in table 2. That these recommendations relate primarily to endemic yeast infections reflects the lack of effective active oral agents for treatment of infections caused by filamentous fungi.
Future Clinical Trials in Which Amphotericin B Should Be the Standard
No significant agent has yet been introduced into the market for treating certain disease entities; future clinical trials will require amphotericin B to be the comparative agent. lists these diseases and gives examples ofthe types of comparative agents that would be needed. The primary emphasis is on filamentous fungi, severe disseminated or meningeal disease, and the more resistant emerging pathogens.
Future Clinical Trials in Which Amphotericin B Should Not Be the Standard
Because of recent trials in which new treatments of choice have been demonstrated or in which amphotericin B and the comparative agent appear to be equivalent, serious consideration should be given to using the less toxic agent for comparison in future trials. These include the following:
1. Candidemia-there are probably subsets of patients with self-limited disease, i.e., who respond to removal of intravenous devices and for whom most therapies will be effective. In other situations, i.e., when non-albicans species are isolated or for shock syndromes in the presence of candidemia, there are still lingering doubts as to the equivalence of fluconazole and amphotericin B [5] . Table 2 . Situations in which treatment with intravenous amphotericin B could be followed by that with oral agents.
2. Low-risk cryptococcal meningitis in patients with AIDS-fluconazole should be the comparative agent [10] . 3. Many ofthe chronic manifestations of disseminated coccidioidomycosis, sporotrichosis, or paracoccidioidomycosis-an azole should be the comparative agent [12] [13] [14] [15] . 4. Nonfulminant histoplasmosis and blastomycosis-itraconazole or ketoconazole should be the comparative agent of choice [3, 16, 17] . In summary, in the last decade there have been a substantial number of clinical trials with new azole compounds in which efficacy comparable to that of amphotericin B has been clearly demonstrated. These data, coupled with modem concepts of ambulatory therapy and managed care economics, should alter previously used treatment patterns. In addition, patients have decreased tolerance for prolonged inpatient intravenous therapy. Even with the general availability of ambulatory intravenous therapy, the costs, complications of intravenous catheterassociated sepsis, and the toxicities of amphotericin B contribute to the formation of new attitudes and practices in the field of clinical mycology. The promise of wider-spectrum, betterabsorbed azoles and other new agents as well as newer formulations of amphotericin B [18] opens the door for a new era in antifungal therapy in which amphotericin B will no longer be the standard comparative agent. Itraconazole or ketoconazole  Itraconazole or ketoconazole  Itraconazole 
